Bohlius J, Schmidlin K, Boué F, Fätkenheuer G, May M, Caro-Murillo AM, et al. HIV-1-related Hodgkin lymphoma in the era of combination antiretroviral therapy: incidence and evolution of CD4+ T-cell lymphocytes. Blood. 9 juin 2011;117(23):6100‑8. Disponible sur: http://www.ncbi.nlm.nih.gov/pubmed/21368291
Bommenel T, Launay O, Meynard JL, Gilquin J, Katlama C, Lascaux AS, et al. Comparative effectiveness of continuing a virologically effective first-line boosted protease inhibitor combination or of switching to a three-drug regimen containing either efavirenz, nevirapine or abacavir. J Antimicrob Chemother. août 2011;66(8):1869‑77. Disponible sur: http://www.ncbi.nlm.nih.gov/pubmed/21636583
HIV-CAUSAL Collaboration, Cain LE, Logan R, Robins JM, Sterne JAC, Sabin C, et al. When to initiate combined antiretroviral therapy to reduce mortality and AIDS-defining illness in HIV-infected persons in developed countries: an observational study. Ann Intern Med. 19 avr 2011;154(8):509‑15. Disponible sur: http://www.ncbi.nlm.nih.gov/pubmed/21502648
Jaffe HW, De Stavola BL, Carpenter LM, Porter K, Cox DR, CASCADE Collaboration. Immune reconstitution and risk of Kaposi sarcoma and non-Hodgkin lymphoma in HIV-infected adults. AIDS. 17 juill 2011;25(11):1395‑403. Disponible sur: http://www.ncbi.nlm.nih.gov/pubmed/21572307
Lanoy E, Guiguet M, Bentata M, Rouveix E, Dhiver C, Poizot-Martin I, et al. Survival after neuroAIDS: association with antiretroviral CNS Penetration-Effectiveness score. Neurology. 15 févr 2011;76(7):644‑51. Disponible sur: http://www.ncbi.nlm.nih.gov/pubmed/21248274
Lanoy E, Rosenberg PS, Fily F, Lascaux A-S, Martinez V, Partisani M, et al. HIV-associated Hodgkin lymphoma during the first months on combination antiretroviral therapy. Blood. 7 juill 2011;118(1):44‑9. Disponible sur: http://www.ncbi.nlm.nih.gov/pubmed/21551234
Lanoy E, Spano J-P, Bonnet F, Guiguet M, Boué F, Cadranel J, et al. The spectrum of malignancies in HIV-infected patients in 2006 in France: the ONCOVIH study. Int J cancer. 15 juill 2011;129(2):467‑75. Disponible sur: http://www.ncbi.nlm.nih.gov/pubmed/21207370
Lodi S, Phillips A, Touloumi G, Geskus R, Meyer L, Thiébaut R, et al. Time from human immunodeficiency virus seroconversion to reaching CD4+ cell count thresholds <200, <350, and <500 Cells/mm3: Assessment of need following changes in treatment guidelines. Clin Infect Dis. 15 oct 2011;53(8):817‑25. Disponible sur: http://www.ncbi.nlm.nih.gov/pubmed/21921225
Mugavero MJ, May M, Ribaudo HJ, Gulick RM, Riddler SA, Haubrich R, et al. Comparative effectiveness of initial antiretroviral therapy regimens: ACTG 5095 and 5142 clinical trials relative to ART-CC cohort study. J Acquir Immune Defic Syndr. 1 nov 2011;58(3):253‑60. Disponible sur: http://www.ncbi.nlm.nih.gov/pubmed/21857357
Mussini C, Cossarizza A, Sabin C, Babiker A, De Luca A, Bucher HC, et al. Decline of CD4+ T-cell count before start of therapy and immunological response to treatment in antiretroviral-naive individuals. AIDS. 15 mai 2011;25(8):1041‑9. Disponible sur: http://www.ncbi.nlm.nih.gov/pubmed/21412128
Pursuing Later Treatment Options II (PLATO II) project team for the Collaboration of Observational HIV Epidemiological Research Europe (COHERE), Castro H, Judd A, Gibb DM, Butler K, Lodwick RK, et al. Risk of triple-class virological failure in children with HIV: a retrospective cohort study. Lancet (London, England). 7 mai 2011;377(9777):1580‑7. Disponible sur: http://www.ncbi.nlm.nih.gov/pubmed/21511330
van der Helm JJ, Prins M, del Amo J, Bucher HC, Chêne G, Dorrucci M, et al. The hepatitis C epidemic among HIV-positive MSM: incidence estimates from 1990 to 2007. AIDS. 15 mai 2011;25(8):1083‑91. Disponible sur: http://www.ncbi.nlm.nih.gov/pubmed/21537114 Writing Committee for the CASCADE Collaboration. Timing of HAART initiation and clinical outcomes in human immunodeficiency virus type 1 seroconverters. Arch Intern Med. 26 sept 2011;171(17):1560‑9. Disponible sur: http://www.ncbi.nlm.nih.gov/pubmed/21949165
